Hasan I, Saif‐Ur‐Rahman KM, Hayat S, et al. - A systematic review was conducted to summarize and meta‐analyze SARS‐CoV‐2‐associated Guillain‐Barré syndrome (GBS) in terms of its main features and prognosis. Between January 1 and August 5, 2020, researchers carried out a search using SARS‐CoV‐2 and GBS‐related keywords in PubMed (Medline), Web of Science, and Cochrane databases for relevant articles published. They recorded data on sociodemographic features, antecedent symptoms, clinical, serological, and electrophysiological characteristics, and hospital outcomes. Forty-five articles from 16 countries reporting on 61 patients with SARS‐CoV‐2‐associated GBS were included in the study. The results of this study indicate that SARS‐CoV‐2‐associated GBS mostly looks like the classical presentation of GBS and that it responds to standard treatments. A demyelinating subtype of GBS was seen in most patients (75.5%). Intravenous immunoglobulin (IVIg) and plasmapheresis were given to 92.7% and 7.3% of patients, respectively. A good outcome (GBS‐disability score ≤ 2) was seen in about two‐thirds (65.3%) of patients on discharge from hospital. Further large‐scale case‐control studies are needed to strengthen the current evidence.